Valneva’s Stock Sinks to the Floor as Investors Weigh Dilution, Legal Risks, and a Vaccine Bet

Valneva shares hit near 52-week low after €84M capital raise dilutes holders, while Lyme vaccine LB6V misses Phase 3 endpoint and legal scrutiny mounts.

The past few weeks have been punishing for Valneva shareholders, and the pain is far from over. The French-Austrian biotech group’s shares are now trading at €2.30, barely above the 52-week low of €2.26 struck in recent days. That marks a decline of roughly 41% since the start of the year, and the gap to the 52-week high of €5.16 — a drop of more than 56% — underscores just how far sentiment has soured.

At the heart of the selloff lies a capital raise that has left existing holders nursing heavy dilution. Late last month, Valneva closed a financing package worth up to €84 million. The immediate tranche of €37 million was raised by placing nearly 16 million new shares at €2.33 apiece, with Frazier Life Sciences leading the round. New investors including Deep Track Capital, Cormorant Asset Management and Perceptive Advisors also came aboard. Each new share carries a warrant, and if all those warrants are exercised, another €47 million would flow into the company’s coffers.

But there is a catch — and it is a big one. The warrants can only be converted after a potential FDA approval for LB6V, Valneva’s Lyme disease vaccine candidate developed with Pfizer. That condition ties the company’s future financing directly to the success of its most important pipeline asset. And that asset has already stumbled badly.

In March, LB6V missed its primary endpoint in a pivotal Phase 3 trial. Valneva and Pfizer attributed the failure to a low disease incidence rate, but the damage was done. Despite the setback, both partners are pressing ahead with regulatory filings in the US and Europe, targeting the second half of 2026. If approval comes through, milestone payments of up to $143 million and tiered royalty streams await. For now, though, the clinical miss hangs over everything.

The stock’s slide has also attracted unwelcome legal attention. US law firm Pomerantz has opened an investigation into potential securities law violations, adding another layer of uncertainty for investors.

Analyst opinion is sharply divided. Goldman Sachs has slapped a sell rating on the stock with a price target of €2.15, while Guggenheim is forecasting first-quarter revenue of €49.1 million — well above consensus estimates. The company itself has guided for full-year 2026 revenue of between €155 million and €170 million, down from €174.7 million in 2025, as third-party sales wind down even as its proprietary vaccine business grows.

On the cost side, Valneva has been cutting aggressively. After consolidating its French operations, the company has launched a fresh restructuring program. The effort helped reduce operating cash burn by 21% in 2025, and year-end cash stood at roughly €110 million. The new capital injection provides some breathing room, but not enough to absorb another disappointment.

All eyes are now on Wednesday, when Valneva reports first-quarter results via a webcast at 3 PM CET. Investors will be scanning the numbers for signs of progress on the restructuring and cash conservation. But the real focus will be on any update regarding the Lyme vaccine program — and whether the company can offer a credible path forward after a clinical trial that has already shaken confidence to its core.